{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:19:30Z","timestamp":1760059170067,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Introduction: The consumption of systemic antifungals is on the rise. However, a significant proportion of systemic antifungal prescriptions is inappropriate. Inappropriately prescribed antifungals are problematic, but there has been minimal emphasis on ensuring the appropriate prescription of systemic antifungals. Local studies regarding the patterns and appropriateness of antifungal prescriptions are also lacking. Materials and Methods: In this retrospective, single-centre, observational study, every in-patient prescription order of systemic antifungals in a regional hospital in Hong Kong between 1 May and 31 July 2023 was reviewed via electronic patient records. The appropriateness of a systemic antifungal prescription was assessed by its indication, dosage, duration and antifungal\u2013concomitant drug interactions by a single reviewer. Results: A total of 177 prescriptions orders were collected. Itraconazole, micafungin and fluconazole were the most prescribed systemic antifungals. The haematology team, infectious disease team and ICU were the major systemic antifungal prescribers in this study. The overall appropriateness of systemic antifungal prescriptions was 27.7% (49\/177), with an appropriateness of 72.9% (129\/177) for indications, 57.1% (101\/177) for dosage, 91.5% (162\/177) for duration and 71.6% (127\/177) for antifungal\u2013concomitant drug interactions. Triazole antifungals had an overall prescription appropriateness of only 15% and were more likely to be prescribed inappropriately than non-triazole antifungals (p &lt; 0.001). Common prescription pitfalls include (i) starting a systemic antifungal for sputum culture that grew Candida spp., (ii) debatable prophylaxis with itraconazole capsules, (iii) overlooking potentially serious antifungal\u2013drug interactions. Conclusions: Inappropriate systemic antifungal prescription is not uncommon in Hong Kong. Establishing an antifungal stewardship programme in public hospitals may be beneficial.<\/jats:p>","DOI":"10.3390\/antibiotics14060556","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T09:47:34Z","timestamp":1748512054000},"page":"556","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Patterns and Appropriateness of Systemic Antifungal Prescriptions in a Regional Hospital in Hong Kong"],"prefix":"10.3390","volume":"14","author":[{"given":"Ryan Y. H.","family":"Leung","sequence":"first","affiliation":[{"name":"Department of Pathology, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmy Y. W.","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Pathology, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"ofw268","DOI":"10.1093\/ofid\/ofw268","article-title":"Trends in Hospitalizations Related to Invasive Aspergillosis and Mucormycosis in the United States, 2000\u20132013","volume":"4","author":"Vallabhaneni","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40265-022-01751-x","article-title":"Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries","volume":"82","author":"Pathadka","year":"2022","journal-title":"Drugs"},{"key":"ref_3","first-page":"2613","article-title":"Appropriateness of antifungal prescribing in Oman","volume":"20","author":"Balkhair","year":"2022","journal-title":"Pharm. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/jac\/dks256","article-title":"Adherence to recommendations for the use of antifungal agents in a tertiary care hospital","volume":"67","author":"Nivoix","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/jac\/dku053","article-title":"Evaluation of antifungal use in a tertiary care institution: Antifungal stewardship urgently needed","volume":"69","author":"Valerio","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s11096-016-0382-6","article-title":"Drug utilization study of systemic antifungal agents in a Brazilian tertiary care hospital","volume":"38","author":"Reis","year":"2016","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ibrahim, S.M., Adlan, N., Alomair, S.M., Butaiban, I., Alsalman, A., Bawazeer, A., Alqahtani, M., Mohamed, D., and Emeka, P.M. (2023). Evaluation of Systemic Antifungal Prescribing Knowledge and Practice in the Critical Care Setting among ICU Physicians and Clinical Pharmacists: A Cross-Sectional Study. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020238"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Valerio, M., Vena, A., Bouza, E., Reiter, N., Viale, P., Hochreiter, M., Giannella, M., Mu\u00f1oz, P., and on behalf the COMIC study group (Collaborative group on Mycosis) (2015). How much European prescribing physicians know about invasive fungal infections management?. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0809-z"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"106255","DOI":"10.1016\/j.ijantimicag.2020.106255","article-title":"Impact of a non-compulsory antifungal stewardship program on overuse and misuse of antifungal agents in a tertiary care hospital","volume":"57","author":"Markogiannakis","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2334-10-150","article-title":"Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: A retrospective cohort study","volume":"10","author":"Zilberberg","year":"2010","journal-title":"BMC Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/AAC.01128-10","article-title":"Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: A prospective multicenter study involving 2441 patients","volume":"55","author":"Lortholary","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"Arendrup","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/21505594.2016.1226721","article-title":"Antifungal stewardship considerations for adults and pediatrics","volume":"8","author":"Hamdy","year":"2017","journal-title":"Virulence"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.cmi.2022.01.027","article-title":"Defining COVID-19\u2013associated pulmonary aspergillosis: Systematic review and meta-analysis","volume":"28","author":"Kariyawasam","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s13054-022-04270-z","article-title":"Impact of COVID-19 pandemic on antifungal consumption: A multicenter retrospective analysis","volume":"26","author":"Bienvenu","year":"2022","journal-title":"Crit. Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2147\/IDR.S451742","article-title":"The Emergence of Candida auris is Not Associated with Changes in Antifungal Prescription at Hospitals","volume":"17","author":"Wong","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref_17","first-page":"FC27","article-title":"Prescribing Pattern of Antifungal Medications at a Tertiary Care Hospital in Oman","volume":"10","author":"Balushi","year":"2016","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1086\/527383","article-title":"Beta-D-glucan detection test: A step toward preemptive therapy for fungal infections in leukemic patients?","volume":"46","author":"Herbrecht","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","unstructured":"Panel on Opportunistic Infections in Adults Adolescents with, H.I.V (2024, June 22). Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America, Available online: https:\/\/www.hivma.org\/news\/news_and_publications\/hivma_news_releases\/2025\/nihs-abrupt-grant-cuts-threaten-hiv-progress-and-global-health-security\/."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/sur.2009.9930","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"11","author":"Solomkin","year":"2010","journal-title":"Surg. Infect."},{"key":"ref_26","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: Summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S1473-3099(21)00191-2","article-title":"Global guideline for the diagnosis and management of the endemic mycoses: An initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology","volume":"21","author":"Thompson","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00134-021-06449-4","article-title":"Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis","volume":"47","author":"Verweij","year":"2021","journal-title":"Intensive Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/DHPS.S80762","article-title":"Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital","volume":"7","author":"Vazin","year":"2015","journal-title":"Drug Healthc. Patient Saf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10096-011-1315-x","article-title":"Use of antifungal agents in pediatric and adult high-risk areas","volume":"31","author":"Borobia","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/jac\/dky098","article-title":"Defensive medicine among antibiotic stewards: The international ESCMID AntibioLegalMap survey","volume":"73","author":"Tebano","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","first-page":"22","article-title":"Antifungal Susceptibility Profile of Candida Species: 5 Years of Experience from a Tertiary Referral Hospital Laboratory in Hong Kong","volume":"33","author":"Cheng","year":"2024","journal-title":"Pathologue"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1469-0691.2012.03891.x","article-title":"A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital","volume":"19","author":"Juan","year":"2013","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/6\/556\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:43:10Z","timestamp":1760031790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/6\/556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["antibiotics14060556"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14060556","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2025,5,29]]}}}